Bapineuzumab for mild to moderate Alzheimer's disease: A meta-analysis of randomized controlled trials

BMC Neurology

Volumn 17, Issue 1, 2017, Pages

  Abushouk, Abdelrahman Ibrahim ^a,b   Elmaraezy, Ahmed ^b,c   Aglan, Amro ^d   Salama, Reham ^e   Fouda, Samar ^f   Fouda, Rana ^f   AlSafadi, Ammar M ^g  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b NovaMed Medical research Association   (Egypt)

^c AL AZHAR UNIVERSITY   (Egypt)

^d TANTA UNIVERSITY   (Egypt)

^e BENHA UNIVERSITY   (Egypt)

^f ZAGAZIG UNIVERSITY   (Egypt)

^g DAMASCUS UNIVERSITY   (Syrian Arab Republic)

Author keywords

Alzheimer's disease; Bapineuzumab; Dementia; Passive immunotherapy

Indexed keywords

BAPINEUZUMAB; PLACEBO; TAU PROTEIN; MONOCLONAL ANTIBODY;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; BRAIN EDEMA; CONVULSION; DELIRIUM; DEMENTIA ASSESSMENT; DISABILITY ASSESSMENT FOR DEMENTIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FALLING; HEADACHE; HUMAN; HYPERTENSION; META ANALYSIS; MINI MENTAL STATE EXAMINATION; NEOPLASM; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN CEREBROSPINAL FLUID LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SYSTEMATIC REVIEW; VOMITING; OUTCOME ASSESSMENT; STATISTICS AND NUMERICAL DATA;

ALZHEIMER DISEASE; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85016955516     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-017-0850-1     Document Type: Article

References (34)

1. Ballard C, Gauthier S, Corbett A, et al. Alzheimer's disease. Lancet. 2011;377:1019-31. doi: 10.1016/S0140-6736(10)61349-9.
2. Xia N, Zhou B, Huang N, et al. Visual and fluorescent assays for selective detection of beta-amyloid oligomers based on the inner filter effect of gold nanoparticles on the fluorescence of CdTe quantum dots. Biosens Bioelectron. 2016;85:625-32. doi: 10.1016/j.bios.2016.05.066.
3. Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71:362-81. doi: 10.1097/NEN.0b013e31825018f7.
4. Chen X, Petranovic D. Role of frameshift ubiquitin B protein in Alzheimer's disease. Wiley Interdiscip Rev Syst Biol Med. 2016;8:300-13. doi: 10.1002/wsbm.1340.
5. Alzheimer's Association. 2013 Alzheimer's disease facts and figures. Alzheimers Dement. 2013;9:208-45.
6. Pahnke J, Walker LC, Scheffler K, Krohn M. Alzheimer's disease and blood-brain barrier function-why have anti-β-amyloid therapies failed to prevent dementia progression? Neurosci Biobehav Rev. 2009;33:1099-108.
7. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet. 2006;368:387-403. doi: 10.1016/S0140-6736(06)69113-7.
8. Bard F, Cannon C, Barbour R, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916-9.
9. Bard F, Barbour R, Cannon C, et al. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci. 2003;100:2023-8.
10. Buttini M, Masliah E, Barbour R, et al. β-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci. 2005;25:9096-101.
11. Shankar GM, Li S, Mehta TH, et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008;14:837-42.
12. Zago W, Buttini M, Comery TA, et al. Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific. J Neurosci. 2012;32:2696-702.
13. Salloway R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman MSR. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73:2061-70. doi: 10.1212/WNL.0b013e3181c67808.
14. Rinne DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, BJ GM. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363-72. doi: 10.1016/s1474-4422(10)70043-0.
15. Black RS, Sperling RA, Safirstein B, et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2010;24:198.
16. Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:322-33.
17. Arai H, Umemura K, Ichimiya Y, et al. Safety and pharmacokinetics of bapineuzumab in a single ascending-dose study in Japanese patients with mild to moderate Alzheimer's disease. Geriatr Gerontol Int. 2016;7:S776-7.
18. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of interventions. The Cochrane Collaboration. 2008. doi: 10.1002/9780470712184.
19. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-64.
20. Gauthier S, Gelinas I, Gauthier L. Functional disability in Alzheimer's disease. Int Psychogeriatr. 1997;9(Suppl 1):163-5.
21. Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43:2412.
22. Harrison J, Minassian SL, Jenkins L, et al. A neuropsychological test battery for use in Alzheimer disease clinical trials. Arch Neurol. 2007;64:1323-9.
23. Stern Y, Albert SM, Sano M, et al. Assessing patient dependence in Alzheimer's disease. J Gerontol. 1994;49:M216-22.
24. Altman DG, Bland JM. Standard deviations and standard errors. BMJ (Clinical research ed). 2005;331:903. doi: 10.1136/bmj.331.7521.903.
25. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34.
26. Rinne JO, Brooks DJ, Rossor MN, et al. 11 C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9:363-72.
27. Blennow K, Zetterberg H, Rinne JO, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol. 2012;69:1002-10.
28. Black RS, Sperling R, Kirby L, et al (2006) A single ascending dose study of bapineuzumab, a humanized monoclonal antibody to A-beta. AD, 9th international Geneva/Springfield symposium on advances in Alzheimer therapy.
29. Sperling R, Salloway S, Arrighi M, et al. Revised estimates of incidence and risk factors for amyloid related imaging abnormalities (ARIA) in the phase 2 studies of bapineuzumab for mild-to-moderate Alzheimer's disease. Alzheimers Dement. 2011;7:e64.
30. Novak G, Di J, Brashear RH, et al. Efficacy and safety of subcutaneous Bapineuzumab. Alzheimers Dement. 2014;10:P446-7.
31. Imbimbo S., Frisardi, V., Solfrizzi, V., Greco, A., Seripa, D., Pilotto, A., Panza, F., B P. O (2012) Solanezumab for the treatment of mild-to-moderate Alzheimer's disease. Expert Rev Clin Immunol 8:135-149. doi: 10.1586/eci.11.93.
32. De la Torre JC. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. N Engl J Med. 2014;370:1459-60. doi: 10.1056/NEJMc1402193#SA2.
33. Chalmers K, Wilcock GK, Love S. APOEε4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of Aβ protein. Neuropathol Appl Neurobiol. 2003;29:231-8.
34. Weller RO, Nicoll JAR. Cerebral amyloid angiopathy: both viper and maggot in the brain. Ann Neurol. 2005;58:348-50.